{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stuart ASV"],"funding":["National Institute for Health Research (NIHR)","Wellcome Trust","Academy of Medical Sciences"],"pagination":["36-49"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8648333"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["399(10319)"],"pubmed_abstract":["Background
Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer-BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).Methods
Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8-1"],"journal":["Lancet (London, England)"],"pubmed_title":["Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial."],"pmcid":["PMC8648333"],"funding_grant_id":["211153/Z/18/Z","CL-2013-01-003","NIHR201409","NF-SI-0617-10010","NIHR202437","AMS-SGCL11-Duncan"],"pubmed_authors":["Greenland M","Ferreira DM","Nguyen-Van-Tam JS","Ramsay M","Read RC","Mujadidi YF","Turner PJ","Cameron JC","Heath PT","Lillie PJ","White R","Liu X","Charlton S","Snape MD","Clutterbuck EA","Singh N","Lazarus R","Darton T","Horsington BM","Hallis B","Plested EL","Duncan CJA","Dinesh T","Collins AM","Hill H","England A","Stuart ASV","Shaw RH","Robinson H","Lambe T","Payne R","Com-COV2 Study Group","Finn A","Turner DPJ","Goodman AL","Screaton GR","Green CA","Ramasamy MN","Andrews NJ","Libri V","Vichos I","Provstgaard-Morys S","Aley PK","Faust SN"],"additional_accession":[]},"is_claimable":false,"name":"Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.","description":"Background
Given the importance of flexible use of different COVID-19 vaccines within the same schedule to facilitate rapid deployment, we studied mixed priming schedules incorporating an adenoviral-vectored vaccine (ChAdOx1 nCoV-19 [ChAd], AstraZeneca), two mRNA vaccines (BNT162b2 [BNT], Pfizer-BioNTech, and mRNA-1273 [m1273], Moderna) and a nanoparticle vaccine containing SARS-CoV-2 spike glycoprotein and Matrix-M adjuvant (NVX-CoV2373 [NVX], Novavax).Methods
Com-COV2 is a single-blind, randomised, non-inferiority trial in which adults aged 50 years and older, previously immunised with a single dose of ChAd or BNT in the community, were randomly assigned (in random blocks of three and six) within these cohorts in a 1:1:1 ratio to receive a second dose intramuscularly (8-1","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-19T10:42:55.248Z","creation":"2022-02-11T15:06:17.075Z"},"accession":"S-EPMC8648333","cross_references":{"pubmed":["34883053"],"doi":["10.1016/S0140-6736(21)02718-5","10.1016/s0140-6736(21)02718-5"]}}